SNY : Analysis & Opinions

  1. 5 Things MannKind's Management Wants You to Know

    May 15, 2015
    MannKind (NASDAQ: MNKD) has always believed that it is on a mission to revolutionize patient treatment. While that might ...
  2. Trade Europe and a Strong USD with this ETF

    April 10, 2015
    With ETFs is't now possible to construct a portfolio of European equities and simultaneously hedge the currency risk.
  3. Inverse Head and Shoulders Patterns Breaking Out

    April 9, 2015
    Watch for higher prices if these stocks complete inverse head and shoulders patterns (a bottoming pattern).
  4. What are examples of major companies in the drugs sector?

    April 1, 2015
    Identify the major players in the drugs sector, which include many established pharmaceutical companies that have delved ...
  5. Four Key Pharmaceuticals ETFs To Consider

    March 25, 2015
    ETF funds are now very liquid investments and are suitable to investors who seek to match the price performance of the indexes ...
  6. Hedge Your European Exposure With This Savvy ETF

    February 9, 2015
    The European Central Bank's (ECB) recent announcement of a huge bond-buying program has made investors understandably giddy. ...
  7. 3 Great Value Stocks For A Secure Retirement

    August 13, 2014
    With the market getting knocked around more this year, investors are understandably on edge. A recent American Association ...
  8. It's No Accident That Drugs Are Expensive

    August 30, 2013
    Branded drugs are expensive in large part because it's expensive and risky to develop them
  9. Novo Nordisk Getting Its Trial By Fire

    August 8, 2013
    Novo Nordisk is facing more challenges than it has in a while, but the growth remains strong.
  10. Can Sanofi Investors Just Blame It On Rio?

    August 6, 2013
    Can Sanofi Investors Just Blame It On Rio? By Stephen D. Simpson, CFA Sanofi (NYSE: SNY) was supposed to be a relatively ...
  11. Taking The Contrarian Approach With European Equities

    July 2, 2013
    Investors continue to shun European equities due to the regions debt issues and economic problems. However, that’s a real ...
  12. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  13. Investing For The Global Diabetes Epidemic

    May 31, 2013
    Sadly, diabetes is quickly becoming a global epidemic. Within these grim statistics, investors can find opportunities with ...
  14. Elan Continues To Make Baffling Strategic Decision

    May 21, 2013
    Elan seems to be set on wasting the Tysabri windfall instead of returning it to shareholders
  15. Another Negative Fish Oil Study Adds To Amarin's Marketing Challenges

    May 9, 2013
    More questions about the real efficacy of fish oil is bad news for Amarin.
  16. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  17. Pharma Is Doing All The Pulling For Johnson & Johnson

    April 17, 2013
    Although JNJ reported decent earnings and has some major new drugs lined up - downside risk is definitely still present.
  18. Pfizer Readies Zoetis For Market

    January 23, 2013
    Pfizer filed further details about its tentative spin-off of Zoetis, its animal health business.
  19. A Look Back At The Year In Pharmaceuticals

    December 28, 2012
    Pharmaceuticals have had a decidedly mixed year in 2012, largely on the basis of the revenue growth outlook.
  20. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  21. Is “Less Bad” As Good As It Gets For Dendreon?

    November 5, 2012
    Dendreon has made progress with its expenses, but the sluggish revenue growth is still the major problem.
  22. Neogen Is Almost Cheap

    December 30, 2011
    Neogen has to do more to validate this price.
  23. 2011's Biggest Mergers and Acquisitions

    December 30, 2011
    M&A activity rebounded in a big way in 2011. Here's a look back at the biggest mergers and acquisitions during the year.
  24. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  25. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  26. Biogen Idec Has Built A Valuable Franchise

    November 1, 2011
    Biogen Idec is a go-to name in MS that carries a lot of value. A credible buy for those with longer horizons.
  27. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
  28. Top Healthcare Dividend Stocks

    July 26, 2011
    Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
  29. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  30. Teva And Cephalon Solve Each Other's Problems

    May 4, 2011
    Teva's acquisition of Cephalon is a logical deal that solves problems for each company.
  31. Novo Nordisk Still One Of The Best Around

    May 3, 2011
    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  32. Buffett Defends These Stocks As Undervalued

    April 1, 2011
    These stocks allow you to invest in some excellent companies, at a wider discount to intrinsic value than what Berkshire ...
  33. A Deal At Last For Sanofi And Genzyme

    February 18, 2011
    Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
  34. Novartis Building Itself Into A One-Stop Shop

    January 26, 2011
    Novartis takes another step into molecular diagnostics.
  35. MannKind And The FDA - Here We Go Again

    January 20, 2011
    MNKD got another FDA setback in its attempts to bring inhaled insulin to the market.
  36. Has Ingenico Done VeriFone A Favor?

    December 23, 2010
    By rebuffing Danaher, Ingencio may be helping VeriFone.
  37. Novartis Brings Alcon Into The Fold

    December 16, 2010
    Novartis closes the deal for Alcon.
  38. The Curious And Complicated Case Of MannKind

    December 15, 2010
    MannKind is a classic high-risk high-reward biotech story.
  39. Merck Makes A Smart Buy

    December 3, 2010
    Merck is making an exciting bet on a possible diabetes breakthrough.
  40. Say Oui To French ADRs

    November 17, 2010
    These three French ADRs may not have been your first choice, but we promise: it doesn't make you un-American to snap them ...
  41. Trick Or Treat For Biodel?

    October 21, 2010
    Will Biodel's upcoming PDUFA date give investors a treat or just leave a sour taste?
  42. Potential Takeout Targets

    October 1, 2010
    While there is no secret formula for identifying the next possible takeover targets, you can often get some worthwhile ideas ...
  43. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  44. Another Setback For Roche Is Bad News For ImmunoGen

    August 27, 2010
    Roche suffers another setback to its key cancer franchise, while ImmunoGen faces a major delay in royalty payments.
  45. Big Pharma's Big Problem

    August 16, 2010
    Big Pharma's best patents are expiring, but it may be able to reinvent itself through acquisitions.
  46. 3 Hearty Healthcare Investments

    August 6, 2010
    Should the broad market find its legs, look for these issues to outperform.
  47. Cancer Vaccines Continue To Show Promise

    July 7, 2010
    Dendreon has put cancer vaccines back in the spotlight, but can they live up to their hype?
  48. Relief With Bristol-Myers Squibb

    May 6, 2010
    BMY's strong reaction after first-quarter earnings seems more like relief, as the company still has many challenges to surmount.
  49. 3 Healthy Healthcare Stocks

    April 6, 2010
    Strong dividends offer additional safety to investors concerned about the bull market's sustainability.
  50. Pharmaceutical Profits That Aren't For The Dogs

    March 15, 2010
    Merck and Sanofi-Aventis recently combined their animal health businesses, lending further evidence to the notion that this ...
  51. Four Healthcare Stocks On Fire

    November 18, 2009
    Fourth healthcare stocks that have brushed aside any potential adversity that could arise from future legislation for the ...
  52. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others.
  53. Swine Flu Vaccine: Quantity Over Quality

    July 20, 2009
    The swine flu vaccine race appears to have multiple winners.
  54. Are the Pros Buying? Is it Important?

    June 22, 2009
    Institutional investment numbers are not always indicative of a stock’s profit potential.
  55. Aging Population Feeds Global Healthcare Demand

    October 30, 2008
    Investing in foreign-based healthcare providers is as important as investing in healthcare providers with a global reach.
  56. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider.
Trading Center